A first-in-human dose escalation Phase 1 clinical trial of RMC-5127
Latest Information Update: 05 Mar 2025
At a glance
- Drugs RMC 5127 (Primary)
- Indications Cancer
- Focus Adverse reactions; First in man
Most Recent Events
- 05 Mar 2025 New trial record
- 26 Feb 2025 According to Revolution Medicines media release, company expect to initiate the trial in 2026.